Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases
PR Newswire —
Patent Covers Combination of FC Epsilon RI-Beta Exon Skipping and MS4A6A Modulation — Strengthening Hoth's Immunology IP Portfolio NEW YORK, Feb. 12, 2026 /PRNewswire-PRWeb/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company advancing breakthrough...